Trial Profile
Phase I Study of Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 22 Jan 2018
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 17 Jan 2018 According to a Bayer media release, data will be present at the American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancer Symposium 2018.
- 15 Nov 2014 New trial record